Valuation: Rezolute, Inc.

Market Cap 412M 362M 341M 311M 582M 39.51B 587M 4.1B 1.59B 20.11B 1.55B 1.51B 65.44B P/E 2026
-6.93x
P/E 2027 * -5.91x
Enterprise Value 412M 362M 341M 311M 582M 39.51B 587M 4.1B 1.59B 20.11B 1.55B 1.51B 65.44B EV / Sales 2026
-
EV / Sales 2027 * -
Free-Float
89.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rezolute, Inc.

1 day-1.50%
1 week-0.25%
Current month-15.99%
1 month-21.36%
3 months-21.67%
6 months+46.47%
Current year+66.95%
1 week 3.73
Extreme 3.73
4.13
1 month 3.66
Extreme 3.665
5.1
Current year 1.87
Extreme 1.87
5.64
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
11.46
10 years 0.72
Extreme 0.72
100
Manager TitleAgeSince
Chief Executive Officer 58 30/01/2013
Director of Finance/CFO 52 23/01/2024
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 04/05/2022
Director/Board Member 55 20/11/2019
Chairman 68 10/02/2019
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Tax

Executive/Senior Manager

-2,267 0.0024%
02/07/26 Tax

Chief Technology Officer

-3,062 0.0035%
02/07/26 Tax

Chief Financial Officer

-3,062 0.0035%
Change 5-day change 1-year change 3-year change Capi.($)
-1.50%-0.25%-55.28%+177.46% 412M
-3.30%+1.19%+54.62%+104.15% 71.94B
-0.12%-3.82%+34.21%+74.86% 59.35B
+2.50%+5.66%+33.00%+21.74% 27.16B
+2.71%-1.96%-13.79%+364.46% 26.54B
+0.81%+0.61%-0.49%-5.14% 24.93B
-1.05%+1.07%+21.45%-10.32% 20.61B
-1.70%-3.35%+146.86%+325.69% 15.03B
+0.21%+1.17%-8.07%+499.10% 14.2B
+2.15%-0.92%+48.93%+169.79% 14.36B
Average +0.07%+0.94%+26.14%+172.18% 27.45B
Weighted average by Cap. -0.36%+0.55%+35.31%+132.42%

Financials

2026 2027 *
Net sales - -
Net income -72.7M -63.94M -60.28M -55M -103M -6.98B -104M -723M -280M -3.55B -273M -267M -11.56B -76.81M -67.57M -63.69M -58.11M -109M -7.37B -110M -764M -296M -3.75B -288M -282M -12.21B
Net Debt - -
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
68
Date Price Change Volume
24/09/26 $3.940 -1.50% 3,868,970
23/09/26 $4.000 -0.99% 1,683,275
22/09/26 $4.040 +3.32% 928,647
21/09/26 $3.910 +1.82% 1,082,718
18/09/26 $3.840 -2.78% 2,527,358
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.940USD
Average target price
7.778USD
Spread / Average Target
+97.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RZLT Stock